This is consistent with the all-Q mutant having noN-glycosylation sites and being glycan-free. of the yeast mating -factor peptide ensured secretion. We thereby produced multiple 10s-of-milligram of rFH. Following endoglycosidase H digestion ofN-linked glycans, rFH (with eight residualN-acetylglucosamine moieties) was purified on heparin-affinity resin and anion-exchange chromatography. Full-length rFH was verified by mass spectrometry and Western blot using monoclonal antibodies to the C-terminus. Recombinant FH is usually a single non-aggregated species (by dynamic light scattering) and fully 4-Aminopyridine functional in biochemical and biological assays. An additional version of rFH was produced in which eightN-glycosylation sequons were ablated by AsnGln substitutions resulting in a glycan-devoid product. Successful production of rFH in this potentially very highly expressing system makes production of therapeutically useful quantities economically viable. Furthermore, ease of genetic manipulation inP. pastoriswould allow production of designed FH versions with enhanced pharmacokinetic and pharmacodynamic properties. Keywords:Protein therapeutic, Age-related macular degeneration, Atypical haemolytic uraemic syndrome, Dense deposit disease, Synthetic gene == Introduction == The human glycoprotein known as complement factor H (FH1; 155 kDa) [1] and [2] is usually a complement regulator that circulates in plasma at 350-600 mg/l [3]. It contains 1213 amino acid residues, 40 disulphide bonds and eightN-glycans [4], and its protein component consists entirely of 20 Rabbit polyclonal to PLD3 CCP modules [5] joined by short linkers[6] (Fig. 1). Factor H acts both in the fluid phase and on surfaces to limit the amplification of the activation-specific complement protein fragment, C3b [7]. It has a strong preference for self, as opposed to foreign, surfaces [8] and [9],i.e.it does not effectively suppress C3b accumulation and propagation around the surfaces of bacteria and other foreign particles. Surface-attached C3b binds to receptors on macrophages and thereby facilitates phagocytosis. It also initiates the complement cascade that has both inflammatory and cytolytic consequences [10] and [11]. Association of C3b with factor B forms C3bBb, which is a C3 convertase, able to cleave C3 to generate further copies of C3b [12]. A reactive thioester uncovered upon C3 cleavage then mediates attachment of C3b to nearby nucleophiles such as may be found on a proximal surface. Consequently, C3b molecules are surface deposited in growing clusters around each progenitor molecule. Thus, in a fire fighting role, FH molecules diffuse over the self surface dealing with outbreaks or clusters of C3b molecules. It is, however, unclear how FH engages with each C3b molecule it encounters [13]. == Physique One. == Summary of complement factor H structure and binding sites. Cartoon of human FH (SwissProt IDP08603) molecule that may have a bent-back overall architecture [72]. Each of 20 CCP modules (ovals) contains ~60 amino acid residues, is-strand rich, and has two disulphide bonds. Positions of notable SNPs (see text) are indicated underlines denote the variant produced in this study. Shading signifies binding sites for C3b and glycosaminoglycans (GAGs) (or both in the case of CCP modules 19 and 20 that also bind to sialic acid). Eight of nine potentialN-glycosylation sites are occupied (as indicated) in the native protein P. pastoris-derived glycans were enzymatically cleaved during preparation of recombinant (r)FH. The eight asparagine residues were mutated to glutamine residues in the All-Q mutant. The two primary C3b-binding sites lie at either end of the FH molecule, and bind simultaneously to one, or possibly 4-Aminopyridine two, C3b molecules [13] and [14]. The N-terminal binding site alone is sufficient both to act as a cofactor for factor I-mediated proteolysis of C3b and to accelerate dissociation of any C3bBb complexes that do form [15]. Bivalent binding 4-Aminopyridine probably helps to retain FH around the host-cell surface over the course of multiple C3b-cleavage events. Polyanion-binding sites on FH specific for glycosaminoglycans and sialic acids selectively enforces residency at self-surfaces [16], [17] and [18]. Thus not only must FH prevail in a running battle against outbreaks of C3b deposition but it must also discriminate between self and foreign tissues. Deficiencies in either of these respects could be dangerous for the host. Individuals with mutations [19], [20], [21], [22] and [23] in FH or autoantibodies to the C terminus [24], [25],[26] and [27] of FH are predisposed to developing the renal thrombotic microangiopathy, atypical haemolytic uraemic syndrome. People with FH deficiency resulting from truncating mutations that lead to low serum FH levels are prone to develop dense deposit disease (DDD) [20], [28], [29] and [30] like the FH/ mouse [31]or FH-deficient Norwegian Yorkshire pig [32]. Two common polymorphisms in the FH gene, I62V in CCP 2 and Y402H in CCP 7 [33], [34], [35] and [36] are associated with a significantly increased life-time risk of developing age-related macular degeneration (AMD)..